MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vor Biopharma Inc. - Common Stock (NQ:VOR)

33.62 -0.19 (-0.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vor Biopharma Inc. - Common Stock

< Previous 1 2 3 Next >
Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer
Dr. Khan brings decades of global medical affairs, commercial, and scientific leadership across multiple therapeutic areas including seven successful product launches 
From Vor Biopharma
Via GlobeNewswire
Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM
From Vor Biopharma
Via GlobeNewswire
Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
From Vor Biopharma
Via GlobeNewswire
Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel
Experienced legal leader brings deep expertise in governance, strategic transactions, and risk management to support Vor Bio’s growth 
From Vor Biopharma
Via GlobeNewswire
Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy
From Vor Biopharma
Via GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor
From Vor Biopharma
Via GlobeNewswire
Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer
Experienced commercial leader to shape launch strategy and global market readiness for telitacicept and future pipeline opportunities 
From Vor Biopharma
Via GlobeNewswire
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors
From Vor Biopharma
Via GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer
From Vor Biopharma
Via GlobeNewswire
Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer
From Vor Biopharma
Via GlobeNewswire
Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Peraso (NASDAQ: PRSO) Volume Surges on Takeover News – More Stocks Inside
Via AB Newswire
Topics Artificial Intelligence Supply Chain
Vor Bio Announces $175 Million Private Placement
From Vor Biopharma
Via GlobeNewswire
Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset
From Vor Biopharma
Via GlobeNewswire
Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
From Vor Biopharma
Via GlobeNewswire
Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
From Vor Biopharma
Via GlobeNewswire
Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference
From Vor Biopharma
Via GlobeNewswire
Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors
From Vor Biopharma
Via GlobeNewswire
Vor Bio Announces $55.6 Million Private Placement
From Vor Biopharma
Via GlobeNewswire
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design
From Vor Biopharma
Via GlobeNewswire
Vor Bio to Participate in the Stifel 2024 Healthcare Conference
From Vor Biopharma
Via GlobeNewswire
Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update
From Vor Biopharma
Via GlobeNewswire
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
From Vor Biopharma
Via GlobeNewswire
New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies
From Vor Biopharma
Via GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update
From Vor Biopharma
Via GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
TOP
Email a Story